Cervical Cancer Epidemiology Analysis and Forecast, 2020-2030

There were 109,891 cases of diagnosed incident cases of cervical cancer in the 8MM in 2020. The number of diagnosed incident cases is expected to increase further at an annual growth rate (AGR) of more than 1% during the forecast period. In 2030, urban China is expected to have the highest number of diagnosed incident cases of cervical cancer. The report cervical cancer epidemiology report provides an overview of the risk factors, comorbidities, and global and historical trends for cervical cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Urban China).

The cervical cancer epidemiology report provides an overview of the risk factors, comorbidities, and global and historical trends for cervical cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It includes a 10-year epidemiological forecast for diagnosed incident cases of cervical cancer. The diagnosed incident cases of cervical cancer are further segmented by age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) in these markets. Diagnosed incident cases of cervical cancer are further segmented by International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis (stage IA, stage IB1-2, stage IB3, stage IIA1, stage IIA2, stage IIB, stage III, stage IVA, and stage IVB), histology subtypes (squamous cell carcinoma, adenocarcinoma, adenosquamous carcinomas, small cell neuroendocrine cancers, and others), biomarkers (MSI, MMR-d, PD-L1 positive, NTRK fusion, and HER2), and HPV status (HPV 16, HPV 18, HPV 31, HPV 33, HPV 45, HPV 52, and HPV 58). The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of cervical cancer.

Overview of cervical cancer epidemiology

For more insights on this report, download a free report sample

What are the market dynamics of cervical cancer epidemiology?

Identifying risk factors like age, HPV, sexual history, smoking, immune system deficiency, oral contraceptives, exposure to diethylstilbestrol, and sexually transmitted infections (STIs) is essential for the prevention and treatment of cervical cancer. Additionally, cervical cancer survivors reported a higher prevalence of comorbidities such as heart disease, liver disease, hypertension, gastrointestinal disease, and musculoskeletal disease.

In 2020, the diagnosed incidence of cervical cancer was highest in urban China, followed by Japan and Germany, and was lowest in the US. The rate of increase was highest in urban China. There is no HPV vaccination program there because of the high prices of imported vaccines, and the coverage of cervical cancer screening remains low. HPV vaccination in Japan began in 2010 for girls ages 12–16 years, with three-dose coverage initially reaching more than 70% of the population. In 2013, two months after a formal inclusion in Japan’s national immunization program, proactive recommendations for the HPV vaccine were suspended following reports of adverse events that have since been found to be unrelated to vaccination. Vaccine coverage subsequently dropped to less than 1% and has remained this low to date.

What are the major segments in cervical cancer epidemiology?

The major segments for cervical cancer epidemiology are the International Federation of Gynecology and Obstetrics stage at diagnosis, histology, biomarker, and human papillomavirus status.

FIGO stage at diagnosis of cervical cancer epidemiology

In the 8 major markets, the highest number of diagnosed incident cases of cervical cancer was in stages IB1-2, followed by stage IA, and stage IIB. Among the 8MM, urban China had the highest number of diagnosed incident cases of cervical cancer in stage IB1-2, followed by Japan and the US.

Histology of cervical cancer epidemiology

The highest diagnosed incident cases of cervical cancer were in squamous cell carcinoma, followed by adenocarcinoma, adenosquamous carcinomas, and small cell neuroendocrine cancers.

Biomarker of cervical cancer epidemiology

In the 8MM, urban China had the highest number of diagnosed incident cases of cervical cancer that were PD-L1 positive, followed by the US and Japan.

Human papillomavirus status of cervical cancer epidemiology

HPV 16 is the most significant type of HPV status, followed by HPV 18. In the 8MM, urban China had the highest number of diagnosed incident cases of cervical cancer that were HPV 16, followed by the US and Japan.

Cervical cancer epidemiology, by segments

For more segment insights, download a free report sample

Market report scope

This report provides:

• An overview of the risk factors, comorbidities, and global and historical trends for cervical cancer in the eight major markets (8MM)
• A 10-year epidemiological forecast for diagnosed incident cases of cervical cancer. The diagnosed incident cases of cervical cancer are further segmented by age in these markets. Diagnosed incident cases of cervical cancer are further segmented by the International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis, histology subtypes, biomarkers, and HPV status. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of cervical cancer.
• Expert analysis of disease trends in the 8MM.
• An easy-to-navigate, interactive epidemiology model which is transparent with consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

• Develop business strategies by understanding the trends shaping and driving the global cervical cancer market.
• Quantify patient populations in the global cervical cancer market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for cervical cancer therapeutics in each of the markets covered.
• Understand magnitude of cervical cancer by FIGO stage at diagnosis, histology subtypes, biomarkers (MSI, MMR-d, PD-L1 positive, NTRK Fusion, and HER2), and HPV status.